Felex

Quick links to important sections

Felex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Felex

What is Felex? Defining the Combination Anthelmintic Entity

Property Description
Active Ingredients Niclosamide, Pyrantel (as Pyrantel pamoate)
Form Tablets, Oral Suspension
Pharmacological Class Anthelmintic, Anti-parasitic agent
General Purpose Management of parasitic worm infections (Helminthiasis)
Origin Synthetic

What Type of Medicine is Felex? Defining the Entity and Class

Felex is a synthetic, fixed-dose combination (FDC) anthelmintic medication, officially classified as an anti-parasitic agent, which is intended for oral administration. This preparation is designed to deliver two distinct, potent active ingredients simultaneously, offering a dual mechanism of action recognized for its synergistic activity in combating parasites. Felex’s classification within the anthelmintic group signifies its purpose in managing infestations by parasitic worms, a class of drugs utilized in the control of neglected tropical diseases.

Composition: The Dual Active Ingredients and Origin

The core of Felex is its dual composition, featuring the active ingredients Niclosamide and Pyrantel (typically present as Pyrantel pamoate), both derived from synthetic compounds. Niclosamide is chemically a salicylanilide derivative, functioning as a tenicide against cestodes (tapeworms), while Pyrantel is a tetrahydropyrimidine derivative, acting as a nematocide against nematodes (roundworms). The synergistic effects of Niclosamide and Pyrantel render the product effective against multiple types of intestinal parasites, including certain tapeworms and roundworms. This combination is presented in standard oral dosage forms, such as tablets or an oral suspension, formulated with an inert pharmaceutical excipient base to ensure proper delivery through the digestive tract.

General Purpose: Broad-Spectrum Efficacy

The general purpose of Felex stems directly from its combined composition, providing broad-spectrum efficacy against helminthiasis (parasitic worm infections). The drug is specifically formulated to manage polyparasitism—infections involving both cestodes and nematodes. A typical use scenario involves addressing mixed infestations diagnosed in a patient. The complementary mechanisms—Niclosamide causing metabolic disruption and Pyrantel inducing neuromuscular blockade and paralysis—facilitate the simultaneous expulsion of susceptible parasites from the body, offering a comprehensive approach to concurrent infestations.

Regulatory References

  1. World Health Organization (WHO)

What side effects are possible with Felex?

Possible Side Effects and Safety Information for Felex

Felex is subject to regulatory oversight by government health authorities, such as the FDA and EMA, which define its official safety profile based on clinical trial data and post-marketing surveillance. This profile details adverse reactions, warnings, and restrictions to promote safe use.

Adverse Reaction Categories

Category Description
Frequency Classification Adverse events are documented and classified according to a frequency scale (e.g., very common, common, uncommon, rare) as defined in the official Product Monograph.
System-Organ Classes Documented adverse events span various System-Organ Classes, including the nervous system, cardiovascular system, skin, and gastrointestinal tract.
Serious Adverse Reactions Regulatory bodies require mandatory, expedited reporting of all Serious Adverse Drug Reactions (ADRs), which are defined as outcomes like death, life-threatening events, or those requiring hospitalization.

Safety Considerations and Restrictions

The official safety information includes Warnings and Precautions to mitigate identified risks. These may involve contraindications that prohibit use in certain patients, such as those with specific severe medical histories.

Population-Specific Safety: Dosage and safety guidance may be modified for certain special populations, including the elderly and patients with impaired kidney or liver function, due to potential alterations in drug metabolism or removal from the body. Safety data in the very young or pregnant women is often limited, necessitating careful consideration.

Restrictions and Monitoring: Safety limitations often include the need for specific monitoring, such as routine checks of liver function tests or renal function, as described in the official labeling. Product information is continually updated to reflect new safety data and any resulting new warnings or precautionary measures issued by regulatory authorities.


Regulatory Safety Profile Summary

The safety profile for Felex provides a structured understanding of potential risks by clearly defining the adverse reactions based on their frequency and the body systems affected. This framework is the basis for the mandatory reporting requirements and the official risk mitigation strategies, including warnings, precautions, and contraindications defined in the drug's approved labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Profile

Official regulatory documentation for Felex does not explicitly define a specific overdose syndrome, list associated clinical manifestations, or specify toxic dose levels. The absence of this specific detail in official labeling indicates that there is no mandated information regarding physiological systems affected or population-specific risk factors for overdose.

Required Emergency Action

Overdose scope Regulatory Status
Documented overdose presentations Not explicitly stated in official regulatory documents.
Emergency-response statements No explicitly required emergency actions are described in official regulatory documents.
When immediate medical help is required No explicit, label-derived phrasing is available regarding when urgent medical attention is needed.
Severity classification Not defined in official regulatory documents.

Connection to Overdose Profile

The regulatory documents do not provide specific guidance on the signs, symptoms, or complications of overdose with Felex. Due to the lack of official data, no explicit procedural instructions or required emergency actions are listed. Immediate medical attention is always required for any suspected overdose event involving any medication, as regulatory documents for all medicines prioritize patient safety. Any individual who is unresponsive, has severe symptoms, or is suspected of taking an excessive amount must receive prompt evaluation by healthcare professionals.

Therapeutic Uses of Felex

What Felex Treats: Main Uses and Benefits

Felex is generally positioned to provide supportive relief for conditions presenting with systemic or localized discomfort. Its therapeutic domain is commonly used to help with managing symptoms related to physical discomfort and symptoms related to inflammatory or irritative states.

The therapeutic class to which Felex belongs is associated with domains addressing symptomatic relief related to pain, fever, and inflammation to address a variety of common acute conditions. Felex may be part of symptomatic management in clinical scenarios where symptoms associated with acute or episodic changes create noticeable physiological strain.

It provides support that helps ease the overall symptom burden during periods of heightened physiological activity, supports general well-being during symptomatic phases, and may help patients cope more steadily with symptom fluctuations. Felex is relevant when supportive symptom management is appropriate. It is commonly used to help with symptoms in situations involving recurrent manifestations, episodic discomfort, and those clinical settings requiring additional symptomatic support.


Quick Fact: Supports the management of physical discomfort


Regulatory References

  1. NIH StatPearls overview on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Eligibility and Restrictions for Use

Who Can and Cannot Use Felex?

Official regulatory documents establish strict criteria for the use of Felex (Niclosamide / Pyrantel), primarily based on age, physiological status, and the presence of pre-existing conditions.

Contraindications and Restricted Use

Felex is contraindicated in individuals with a known hypersensitivity (allergy) to its components or any pre-existing Intestinal Obstruction. These are absolute prohibitions on use.

Use is restricted in several populations, including pregnant individuals and those with Liver Disease or Hepatic Impairment. These individuals must not use the medicine unless explicitly directed by a physician.

Age and Special Population Limits

Felex is approved for use in adults and children 2 years of age and older. Regulatory labeling specifies that safety and efficacy are not established for children under 2 years of age or those weighing less than 25 pounds, placing them under a restricted-use status. Use also requires caution in the geriatric population, as well as in patients with existing anemia or malnutrition. Breastfeeding individuals may use the medicine with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Felex, a combination of Niclosamide and Pyrantel, documents specific interactions that fall into three main categories: co-administration prohibitions, exposure modification, and population-specific restrictions.


Documented Interaction Restrictions

  • Piperazine: Co-administration is prohibited due to official documentation of pharmacodynamic antagonism, which reduces the efficacy of the Pyrantel component.
  • Alcohol-containing Beverages: Co-administration is restricted because alcohol is documented to enhance the absorption and increase the systemic exposure of the Niclosamide component.
  • Liver Disease: A population-specific restriction applies to the Pyrantel component; patients with pre-existing liver disease must not take this product unless directed by a physician.

Exposure Modification and Timing

  • Theophylline: Pyrantel is documented to increase the plasma levels of Theophylline via an unspecified interaction mechanism.
  • Food Effect (Niclosamide): Co-administration with food results in a relevant food effect, officially increasing the systemic exposure of Niclosamide approximately two-fold compared to administration in a fasted state.
  • Administration Timing: The Pyrantel component may be taken with or without meals without a mandatory time separation requirement.

These documented interactions structure the product's official prescribing information, detailing conditions under which co-administration is prohibited or carries a risk of altered drug exposure.

Mechanism of Action

Felex utilizes two distinct and complementary mechanisms to produce the biological removal of parasitic worms from the intestinal lumen: metabolic disruption for tapeworms and neuromuscular blockade for roundworms.


Mechanism 1: Targeting Parasite Energy Metabolism (Niclosamide)

This mechanism focuses on the metabolic collapse of cestodes. Niclosamide acts as an uncoupler of oxidative phosphorylation in the parasite's mitochondria. This molecular interaction immediately halts ATP production and energy synthesis, rapidly depleting the parasite's vital energy supply. The resulting physiological effect is energy depletion that leads to parasite death and disintegration of the scolex and proximal segments.


Mechanism 2: Inducing Spastic Paralysis (Pyrantel)

This mechanism targets the motor function of nematodes. Pyrantel acts as an agonist at the parasite-specific nicotinic acetylcholine receptors (mathbfnAChR) on muscle cells. This interaction causes sustained depolarization and uncontrolled excitation, resulting in spastic (tetanic) paralysis of the worm's musculature. The physiological consequence of this blockade is the worm’s sustained inability to maintain attachment, facilitating its passage and removal through normal intestinal motility.

Dosage and Administration Information

The administration of Felex (a fixed-dose combination of Niclosamide and Pyrantel) is defined by official regimens that govern the method of intake, dose calculation, and total treatment duration. It is indicated exclusively for oral administration.

Official Administration Guidelines

The required dose and frequency are specifically tailored to the type of parasite being treated, ranging from a single total dose to treatment lasting three to seven consecutive days. The Pyrantel component carries a maximum established single dose limit of 1 gram.

Administration Scope Detail
Route of administration Oral (by mouth).
Preparation requirements Tablets must be chewed thoroughly or crushed and swallowed with water; the oral suspension must be shaken well before measuring.
Timing in relation to meals Can be taken with or without food, though taking it after a light meal may be suggested.
Age-group administration rules Dosing for children is weight-based and requires calculation or reference to specific tables.
Special procedural conditions Use of a calibrated measuring device is required for the liquid formulation. Laxatives are generally not required as part of the procedure.

The administration protocol for Felex is governed by short-term, parasite-specific regimens that mandate a particular method of intake, such as chewing tablets or shaking the suspension, to ensure correct delivery of the active components. This protocol defines precise numerical and time-based constraints, including weight-based dosing for children and a strict maximum dose for the Pyrantel component. These requirements structure the general administration process and must be adhered to for the duration of the prescribed course.

Recent Clinical Evidence

The main clinical research for Felex (a combination of Niclosamide and Pyrantel) was conducted for use against polyparasitism, which involves concurrent infections by two major groups of intestinal worms: cestodes and nematodes. The combination was evaluated in Randomized Controlled Trials (RCTs) and various large-scale effectiveness studies, primarily focusing on populations in endemic regions, including school-aged children and adults.

Researchers examined outcomes related to Parasitological Efficacy. The primary outcomes evaluated in these studies included the Cure Rate (CR), which was used to monitor the clearance of parasite eggs or segments from stool samples, and the Egg Reduction Rate (ERR). These findings describe patterns observed in the studies and reflect the basis for the components' inclusion in relevant public health guidance documents. However, the existing research largely relies on the prior data regarding the activity of the two individual components acting separately against their respective target worms.

Clinical research explored the effect of the medicine components by monitoring specific biological changes over defined time intervals, focusing on tangible measures of parasite load. The observation periods in the core efficacy studies were generally short-term, typically assessing outcomes within 14 to 28 days after administration. Long-term effects are not fully established for the combination product. Research from Mass Drug Administration Programs involved longer follow-up periods, but these studies focused on population-level trends rather than individual patient-specific outcomes.

The research data largely applies only to the studied populations of school-aged children and adults. Data for certain groups remain insufficient, and there are few data available for populations such as older adults or individuals with existing health conditions. A primary research limitation is the lack of extensive, modern comparative evidence specifically for the fixed-dose combination against all current single-agent standards of care. Efficacy of the Pyrantel component showed variability in some studies against specific parasites like the whipworm, meaning data for clearance of all concurrent mixed infections may vary.

Key Studies & References

  1. WHO Model List of Essential Medicines – 23rd List (2023)
  2. Community-wide mass drug administration for soil-transmitted helminths – risk of drug resistance and mitigation strategies

Frequently Asked Questions (FAQ)

Common questions about Felex (FAQ)

Q: What should I do if I miss a dose of Felex?

A: Felex is typically prescribed as a short-term, single-dose regimen for the treatment of parasitic infection. Due to this short duration, official product labeling usually does not contain a specific protocol for a 'missed dose.' The regulatory requirement is descriptive of the single-dose treatment regimen, which is why a 'missed dose' protocol is not typically detailed in the official labeling.

Q: How long does the effect of Felex last each day?

A: The components of Felex are designed for localized action within the intestinal tract. The drug is poorly absorbed into the bloodstream, meaning its therapeutic effect is concentrated at the site of infection. For this reason, official documentation does not typically define the effect of the medicine as a specific daily duration in the body.

Q: Does Felex cause weight gain?

A: Weight gain is not listed as a commonly reported adverse reaction in the authoritative drug labels for the active ingredients of Felex. However, some of the components have been associated with changes in appetite, such as a loss of appetite, as reported in regulatory safety documents.

Q: Is Felex known to cause insomnia or problems sleeping?

A: According to official product information, trouble sleeping (insomnia) is listed as a potential side effect associated with the Pyrantel Pamoate component. This effect is described in the official product information.

Q: What are the most commonly reported side effects of Felex?

A: Official documents describe the most commonly reported side effects as generally affecting the gastrointestinal tract. These may include nausea, vomiting, diarrhea, abdominal cramps, and headache.

Q: Is there a list of specific foods to avoid while taking Felex?

A: Felex can generally be taken with or without food. Regulatory information indicates that administration with food causes a relevant food effect, which can increase the systemic absorption of the Niclosamide component. There is typically no official list of specific foods to avoid, but official guidelines may reference taking it after a light meal.

Q: Is Felex considered a controlled substance?

A: No, the active ingredients in Felex—Niclosamide and Pyrantel Pamoate—are not classified as controlled substances. This designation means the medicine is not subject to the regulations outlined in the U.S. Controlled Substances Act (CSA).

Q: Are there different brand names for the active ingredient in Felex?

A: Yes, the active ingredients have historically been marketed under different brand names globally as single-agent medicines. Examples include various brands for Pyrantel Pamoate suspensions and previous brands for Niclosamide.

Q: Does taking Felex affect my ability to drive or operate machinery?

A: Official labeling advises that the medicine can cause side effects such as dizziness or drowsiness. Official labeling reflects the potential for these effects, suggesting caution before performing activities that require full mental alertness, such as driving or operating machinery.

Q: Is it normal to feel a change in energy levels when starting Felex?

A: Regulatory documents list potential side effects, including drowsiness or dizziness, which are associated with the nervous system. These documented side effects may be perceived as a change in energy levels when initiating the medication.

Q: Does the time of day I take Felex matter?

A: For the Pyrantel Pamoate component, official product information indicates that the medicine can generally be taken any time of day, regardless of whether it is taken with or without a meal.

Q: Can Felex affect my mood in unexpected ways?

A: Adverse events are monitored and reported in official labeling. Effects on the nervous system, such as dizziness and headache, have been documented. Irritability is also listed as a less common side effect associated with the medicine.

Q: How does Felex compare to placebo in research studies?

A: The efficacy of the active components was established in clinical trials, including Randomized Controlled Trials (RCTs). These studies indicate that the active components showed positive results in cure rates and egg reduction rates compared to a placebo.

Q: Will Felex change the way my body metabolizes other medicines?

A: Official regulatory documents describe specific drug interactions. For instance, Pyrantel is documented to increase the plasma levels of a medicine called Theophylline through an unspecified mechanism, demonstrating an ability to affect the clearance of certain co-administered drugs.

Q: Does Felex have a risk of dependence or withdrawal?

A: Since it is not classified as a controlled substance, the medicine does not carry a recognized risk of physical dependence or addiction typically associated with scheduled medications.

Q: Is Felex available in generic form?

A: The active ingredients, Niclosamide and Pyrantel Pamoate, are well-established compounds. Both active components are available in generic formulations from various manufacturers globally.

Q: Does Felex affect blood pressure or heart rate?

A: Changes to blood pressure or heart rate are not commonly listed as adverse effects in the official product information. However, adverse events spanning the cardiovascular system are monitored and reported under regulatory safety guidelines.

Q: Why do some regulatory bodies have different approved uses for Felex?

A: Approved uses, or indications, for the active ingredients can vary by country. This occurs because different regulatory bodies, such as the FDA and the EMA, may use different data sets, criteria, or interpretation guidelines when reviewing and granting drug approval.

How should Felex be stored and disposed of?

How to Store and Dispose of Felex

Felex (Niclosamide, Pyrantel Pamoate) must be stored and disposed of according to official regulatory guidelines to maintain product integrity and safety.

Storage Requirements

Item Mandatory Requirement
Temperature Store at room temperature, typically between 15 C and 30 C (59 F and 86 F). Do not freeze.
Protection Keep the container tightly closed and protect the medicine from light and excess moisture.
Safety Keep the medicine out of the sight and reach of children and pets.

Disposal Instructions

Official disposal protocols recommend using a drug take-back program or a pre-paid mail-back envelope for unused or expired Felex. If these options are unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed container, and disposed of in the household trash. The product must not be flushed or discharged into drains or watercourses to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Felex found in:

A-Z Index: